Company intelligence / Profile preview

Circularis Biotechnologies

Oakland, California, United States

Ownership: Private
Development stage: Other

Overview

Circularis Biotechnologies developed a proprietary platform using circular RNA and ultra-high-throughput promoter screening to optimize gene expression for bioproduction and gene therapy. The technology enables precise control over the amount and location of protein expression, with applications in gene and cell therapy, rare diseases, and cancer. Circularis has been acquired by Ginkgo Bioworks, and its technology is being integrated to enhance Ginkgo’s capabilities in advanced therapeutics, especially in cell and gene therapy partnerships[2][5][7].

Therapeutic areas: OncologyRare Diseases
Modalities: Gene therapyCell therapyRNA therapyCircular RNA
Industry: Biotech

Partnerships

BiogenSelecta BiosciencesModernaAldevron

Beyond the preview

Go deeper on Circularis Biotechnologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Circularis Biotechnologies.

Explore the full profile